X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will focus on Healis’ upcoming clinical trial studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for the treatment of neuropsychiatric conditions, including Major Depressive Disorder (MDD), PTSD, and Social Anxiety Disorder (SAD).
Lead Product(s): CKDB-501A
Therapeutic Area: Psychiatry/Psychology Product Name: CKDB-501A
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Healis Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 26, 2024
Details:
The collaboration aims to study the second-generation topical treatment for precancerous skin conditions (such as actinic keratosis) and non-melanoma skin cancers that is highly selective for cancer cells while being well-tolerated by normal skin.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Derm-Biome Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 28, 2023
Details:
TRP-8802 (Oral psilocybin) in patients withIrritable Bowel Syndrome, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with Irritable Bowel Syndrome.
Lead Product(s): Psilocybine
Therapeutic Area: Gastroenterology Product Name: TRP-8802
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Tryp Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
NeuroSense & Massachusetts General Hospital will explore the neurotherapeutic effects of PrimeC, utilizing a novel in vitro model generated from post-mortem ALS brain tissue. PrimeC is a novel unique fixed-dose combination of ciprofloxacin and celecoxib.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: NeuroSense Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 27, 2023
Details:
Under the terms of the agreement, Harvard Medical School will initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.
Lead Product(s): Undislcosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Voltron Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 28, 2023
Details:
ABBV-CLS-7262 targets eIF2B, a key regulator of the ISR, a pathway activated in people with ALS. In neurons exposed to cellular stressors, inhibition of the ISR by ABBV-CLS-7262 restores protein synthesis and dissolves pre-formed TDP-43 containing stress granules.
Lead Product(s): ABBV-CLS-7262
Therapeutic Area: Neurology Product Name: ABBV-CLS-7262
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
LUM-201 (ibutamoren) is an orally administered small molecule that promotes the secretion of Growth Hormone from the pituitary gland. This investigator-initiated Phase 2 trial is a single-site, 6-month, open-label pilot study of daily oral LUM-201 in adults with NAFLD.
Lead Product(s): Ibutamoren
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Lumos Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 05, 2022
Details:
SYN-020 is a recombinant bovine Intestinal Alkaline Phosphatase (IAP) formulated for oral delivery to the small intestine. The amended agreement include intellectual property and technology related to the use of SYN-020 intestinal alkaline phosphatase.
Lead Product(s): Recombinant Bovine Intestinal Alkaline Phosphatase
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SYN-020
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Theriva Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: licensing agreement August 03, 2021
Details:
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announced five projects selected to receive funding for clinical and preclinical evaluation of abemaciclib.
Lead Product(s): Abemaciclib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Comprehensive Cancer Network
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding December 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
